BLTE

Belite Bio
BLTE

$49.65
0.1%
 

About: Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Employees: 20

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 6 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

0.42% less ownership

Funds ownership: 0.61% [Q4 2023] → 0.2% (-0.42%) [Q1 2024]

35% less funds holding

Funds holding: 17 [Q4 2023] → 11 (-6) [Q1 2024]

69% less capital invested

Capital invested by funds: $7.1M [Q4 2023] → $2.23M (-$4.87M) [Q1 2024]

75% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 8

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 6

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$57
15%
upside
Avg. target
$59
18%
upside
High target
$59
19%
upside

6 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Yi Chen
19%upside
$59
Buy
Reiterated
13 Jun 2024
Benchmark
Bruce Jackson
15%upside
$57
Buy
Reiterated
16 May 2024
HC Wainwright & Co.
Yi Chen
19%upside
$59
Buy
Reiterated
15 May 2024
HC Wainwright & Co.
Yi Chen
19%upside
$59
Buy
Maintained
22 Mar 2024
HC Wainwright & Co.
Yi Chen
19%upside
$59
Buy
Reiterated
13 Mar 2024

Financial journalist opinion